Physician profile
Olena Gordon
NPI 1528309705
$2,463.14
in general payments reported to CMS, 2019-2025
30 companies · $284 in 2025
The $284 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $375 · 2020: $635 · 2021: $476 · 2022: $18.75 · 2023: $149 · 2024: $524 · 2025: $284.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $957.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $957.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $378.54 | 2019-2024 | Wegovy, Rybelsus, Ozempic |
| Amgen INC. | $204.56 | 2019-2025 | Repatha, Otezla, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $202.63 | 2019-2025 | Xifaxan |
| Abbvie INC. | $196.91 | 2019-2021 | |
| Aimmune Therapeutics, INC. | $196.73 | 2024-2025 | Zenpep |
| Arbor Pharmaceuticals, INC. | $160.92 | 2019-2021 | |
| Pfizer INC. | $125.85 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $101.79 | 2020-2024 | Airsupra, Breztri |
| Janssen Pharmaceuticals, INC | $94.70 | 2021 | |
| Glaxosmithkline, LLC. | $79.65 | 2020-2025 | Bexsero, Pediarix, Rotarix |
| Cranial Technologies, INC | $69.38 | 2019-2021 | |
| Medtronic, INC. | $63.64 | 2025 | Venaseal |
| Nestle Healthcare Nutrition INC. | $63.64 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.23 | 2020-2021 | |
| Horizon Therapeutics Plc | $58.90 | 2020-2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $58.35 | 2019 | |
| Spineology INC. | $34.80 | 2020 | |
| Vivus LLC | $32.66 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $29.46 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $29.18 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $27.08 | 2021-2024 | Trintellix |
| Corium, LLC | $26.98 | 2023 | Adlarity |
| Otsuka America Pharmaceutical, INC. | $25.59 | 2023 | Rexulti |
| Optinose US, INC. | $24.54 | 2020 | |
| Exact Sciences Corporation | $24.26 | 2024 | Cologuard Collection Kit |
| Shield Therapeutics INC | $21.34 | 2024 | |
| Amarin Pharma, INC. | $20.28 | 2020 | |
| Lundbeck LLC | $19.29 | 2024 | Rexulti |
| Philips North America LLC | $17.11 | 2020 | |
| Smith+Nephew, INC. | $14.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Olena Gordon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.